Safety and efficacy of enfortumab vedotin for locally advanced or metastatic urothelial carcinoma in patients aged 80 years and older: A multicenter retrospective study in JapanYuki Kobari, Toshio Takagi, Junpei Iizuka et al.|Journal of Geriatric Oncology|2025Cited by 1
Association between enfortumab vedotin and renal function in metastatic urothelial carcinoma: A multicenter retrospective study in JapanYuki Kobari, Toshio Takagi, Junpei Iizuka et al.|Research Square|2025Cited by 0
Renal Function With Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study in JapanYuki Kobari, Toshio Takagi, Junpei Iizuka et al.|Anticancer Research|2025Cited by 0
Pathologic Complete Response After Enfortumab Vedotin Plus Pembrolizumab in Node-positive Upper Tract Urothelial CarcinomaKayo Kikuchi, Toshio Takagi, Yuki Kobari et al.|In Vivo|2026Cited by 0
Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinomaKazutaka Nakamura, Toshio Takagi, Kazuhiko Yoshida et al.|International Urology and Nephrology|2026Cited by 0